ROVI.MC LABORATORIOS FARMACEUTICOS ROVI
Healthcare · Drug Manufacturers - Specialty & Generic
59.70
+2.93%
About the company
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
52-week range
Dividend deep dive
LABORATORIOS FARMACEUTICOS ROVI (ROVI.MC), operating in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector, has a market capitalization of 3,002,475,520 EUR. The current dividend yield is 1.77%, which sits near its 5-year average of 1.64% and within its historical 5-year range of 0.66% to 2.67%. The company holds a dividend rating score of 7.0.
Dividend history
ROVI.MC has not established a consistent dividend increase streak, showing 0 consecutive years of dividend growth. The 3-year dividend CAGR is -0.72%, indicating a slight recent decline, while the 5-year dividend CAGR stands at 39.80%. Historical dividend payments (in EUR) include: 0.1612 (2014), 0.169 (2015), 0.139 (2016), 0.183 (2017), 0.1207 (2018), 0.0798 (2019), 0.1751 (2020), 0.3812 (2021), 0.9556 (2022), and 1.2938 (2023). Projected dividends for 2024 are 1.1037 EUR and for 2025 are 0.9351 EUR.
Dividend safety
The company's dividend appears covered with a payout ratio of 37.21% of earnings. The balance sheet shows low leverage, with a debt-to-equity ratio of 16.664.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Appears in these lists
ROVI.MC qualifies for these curated dividend rankings.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track ROVI.MC and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →